(Q33948583)

30 July 2017

title

Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling (English)

1 reference

30 July 2017

0 references

0 references

Kim SW

1

1 reference

30 July 2017

Grant JE

series ordinal

2

1 reference

30 July 2017

Adson DE

series ordinal

3

1 reference

30 July 2017

Shin YC

series ordinal

4

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

30 July 2017

published in

Biological Psychiatry

1 reference

30 July 2017

volume

49

1 reference

30 July 2017

issue

11

1 reference

30 July 2017

page(s)

914-921

1 reference

Pathological gambling and depression.

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

Food reward: brain substrates of wanting and liking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

Fluvoxamine in the treatment of compulsive buying

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Naltrexone and cyclazocine. A controlled treatment study

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

Naltrexone-induced dysphoria in former opioid addicts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

The assessment of anxiety states by rating

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

A rating scale for depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

Pharmacological adjuncts in the treatment of opioid and cocaine addicts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

Short-term single-blind fluvoxamine treatment of pathological gambling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

The use of opiate antagonists in treating bulimia: a study of low-dose versus high-dose naltrexone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

Behavioral effects of naloxone infusion in obsessive-compulsive disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

Opioid Antagonists in the Treatment of Impulse-Control Disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

A preliminary report on possible naltrexone and nonsteroidal analgesic interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

Cognitive effects of high-dose naltrexone in patients with probable Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gamblers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

Pathological gambling among high school students

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

Affective disorders among pathological gamblers seeking treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

Are impulse-control disorders related to bipolar disorder?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

High-dose naltrexone therapy and dietary counseling for obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

Placebo-Controlled Study of Fluvoxamine in the Treatment of Patients With Compulsive Buying

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

Prevalence, assessment, and treatment of pathological gambling: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

Naloxone abolishes obsessive-compulsive behavior in Tourette's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

Estimating the prevalence of disordered gambling behavior in the United States and Canada: a research synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

The prevalence and demographics of pathological gamblers: implications for public health.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

Naltrexone in the treatment of alcohol dependence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

Cognitive and behavioral treatment of pathological gambling: a controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901079-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(01)01079-4

1 reference

30 July 2017

1 reference